🌐Enhance your hematology knowledge with HemeHub webinars, available anytime.

All past sessions are organized by topic directly on our website and are also available on YouTube.

🔗 Learn more at hemehub.org

#HemeHub #Hematology #HemeEd #HemeOnc #BMF #Lymphoma #BleedingDisorders #ThromboticDisorders

Donate to Support Danny Reyes's Cancer Journey, organized by John Benavides Uncle Danny has always been the kind of person who shows up, no matter what. Growi… John Benavides needs your support for Support Danny Reyes's Cancer Journey

My family would really appreciate any donations towards my Tio's journey with his recent lymphoma diagnosis. He's a wonderful person and is ALWAYS helping others out 💜 #cancer #lymphoma #donations #donate #gofundme

Is CAR T-cell therapy right for you?

Learn about candidates, risks, outcomes, and quality of life after treatment.

🗓 May 5
🕞 3:45 p.m. ET | 2:45 p.m. CT | 1:45 p.m. MT | 12:45 p.m. PT

Register: bmtinfonet.org/registration...

#CARTCellTherapy #Lymphoma #BMTInfoNet #CancerSurvivorship

In patients with R/R follicular #lymphoma, treatment with the triplet combo of #tafasitamab, #lenalidomide, and #rituximab led to significantly improved PFS compared with the SOC combo of lenalidomide plus rituximab, at a median 22.4 months vs. 13.9: https://ow.ly/PSaT50YBgcw
#HemeSky

Sickle Cell Disease: From Diagnosis to Cure by #MelissaFreiJones: ASPHO is proud to partner with Mediaplanet in the Blood Health supplement in USA TODAY 3/25-27. #BloodDisorder—including #blood #cancers #leukemia #lymphoma #multiplemyeloma #research uthealthsa.bsky.social

Targeting UHRF1 induces regression of aggressive mantle cell lymphoma - PubMed Although targeting the ubiquitin-like PHD and RING finger domain-containing protein 1 (UHRF1) has shown promise in treating a number of diseases, its function in mantle cell lymphoma (MCL) and its regulatory connection to SOX11 are yet unknown. Our study showed that UHRF1 is markedly upregulated in …

A new target identified - something to watch for the treatment of Mantle Cell #lymphoma Targeting UHRF1 induces regression of aggressive mantle cell lymphoma Preclinical. No trials yet.
share.google/aimode/GHnPt...

pubmed.ncbi.nlm.nih.gov/41876725/

🩸 #sfh2026 #Hematology #OncoHematology #Waldenström #IWMF #Immunology #Lymphoma #WomenInSTEM #GustaveRoussy #WeillCornell #StemCells #ApostolouLab #MelnickLab

Single-cell and #SpatialTranscriptomics of primary testicular #DLBCL reveal an exhausted CD8⁺ T cell–dominated microenvironment and spatial immune architecture, with E2F and CREB inhibition suppressing #lymphoma proliferation and #tumor growth.

#OpenAccess: doi.org/10.1016/j.ge...

Looking into lymphoma treatment abroad?

Mexico offers advanced immunotherapy like checkpoint inhibitors and CAR T-cell therapy. 
www.placidway.com/answer-detail/571379/Wha...

#Lymphoma #Immunotherapy  #MedicalTourism

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

This study aims to unravel relationship b/w apolipoprotein C1 levels, prognostic nutritional index, and clinicopathological characteristics in patients with diffuse large B-cell #lymphoma and their prognostic predictive value.

journals.sagepub.com/share/4YV5WF...

@womeninlymphoma.bsky.social

Influencer Dies at 29 After Mistaking Initial Cancer Symptoms as Strain from Work Wang Weiqian revealed her lymphoma diagnosis in 2021, and she continued to document her health journey for over 18,000 social media followers

#Discover #Cancer #WangWeiqian #Lymphoma 💔🌹

www.yahoo.com/entertainmen...

Your story matters. By sharing your experience in the Global Patient Survey on Lymphomas & CLL, you help drive better care, smarter research and real change worldwide.

Take part today: bit.ly/LCSurveyInfo

#GlobalPatientSurvey #PatientExperience #Lymphoma #CLL #PatientVoice

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma FDA approved approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for cHL.

The FDA has approved nivolumab (Opdivo) with AVD chemotherapy as first‑line treatment for stage III–IV classical Hodgkin lymphoma in patients 12 and older, officially bringing immunotherapy into frontline care. #Lymphoma #Immunotherapy #TCSC
www.fda.gov/drugs/resour...

As the Global Burden of Hodgkin Lymphoma Decreases, Disparities Persist Incidence of Hodgkin lymphoma has decreased globally and is projected to continue to decrease through 2035, but lower SDI regions demonstrated more modest decreases in HL incidence and mortality.

Analysis of #HodgkinLymphoma burden from 1990–2019 reveals a 31.2% increase in global cases. Significant disparities persist in mortality rates and access to care across varying sociodemographic regions.

Read the review: ➡️ https://bit.ly/4uMFfui

#lymsm #globalhealth #lymphoma

EPA moves to weaken pollution limits on chemical used to sterilize medical equipment The Environmental Protection Agency has proposed weakening air pollution limits for a chemical used to sterilize medical equipment.

#MAHA needs to stop the #EPA proposal to weaken pollution limits on ethylene oxide (#EtO), a cancer-causing chemical.

Breathing it long-term significantly increases the risk of developing #leukemia, #lymphoma, and #breastcancer for facility workers and the people living nearby.

High-Dose Cytarabine Maximizes CD34 Cell Yield Without Improving Survival in PCNSL High-dose cytarabine achieved 100% stem cell mobilization success in PCNSL patients undergoing autologous transplantation.

High-dose cytarabine (HD-Ara-C)-based mobilization achieved universal stem cell collection and the highest CD34⁺ yields in primary central nervous system lymphoma (#PCNSL), yet did not confer a progression-free survival advantage.

Read more: https://bit.ly/4rGQcuL

#RareDisease #Lymphoma

Among patients with follicular #lymphoma, adding #epcoritamab to the SOC combo of #lenalidomide plus #rituximab outperformed lenalidomide plus rituximab alone, resulting in ORRs of 95% vs. 79%, as well as a lower risk of disease progression or death: https://ow.ly/652R50YrQeT
#HemeSky #MedSky

A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies - PubMed CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in relapse and/or refractory B-cell malignancies. Up to 30% to 60% of patients experience relapsed disease because of the emergence of CD19low or CD19- tumor cell clones. Although bispecific CD19/CD22 CAR T cells hav …

B-cell #Lymphoma treatments continue to advance: you can target and kill the mature forms of b-cells and more will regenerate from stem cells. The immature cells don't yet have the cd20, or cd19, or cd22 molecule on the cell surface.

pubmed.ncbi.nlm.nih.gov/41100732/

The Targeted Pulse: Updates in Breast, Lung, and Lymphoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Oncology shifts fast: tazemetostat pulled, giredestrant PFS miss, and new ADC and NSCLC guideline strategies refine metastatic care.

Cancer treatment never stands still. New updates across #breastcancer, #lungcancer and #lymphoma show how rapidly #oncology is evolving, with new ADC strategies, trial results and guideline shifts shaping metastatic care.
#OncologyNews #CancerResearch #TCSC
www.targetedonc.com/view/the-tar...

Original post on masto.ai

…inhaling the gas can cause coughing, dizziness, fatigue & nausea. Long-term exposure can damage the #brain & central nervous system & can increase the risk of breast #cancer, #leukemia, #lymphoma & other #cancers of the white blood cells.

The #EPA first classified #EthyleneOxide as a human […]

Researchers identified proteomic markers for #LymphoidCancer risk up to 10yrs before diagnosis. This large-scale discovery reveals how early molecular signatures like sCD23 can drive risk stratification & #EarlyDetection

rdcu.be/e6GBZ%E2%80%8B

#Proteomics #PrecisionMedicine #Biomarkers #Lymphoma

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma - PubMed This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using …

New study led by Dr. Iris Isufi shows liso-cel has strong real-world effectiveness in R/R large B-cell #lymphoma (ORR 81%, CR 71%) with consistent outcomes even in high-risk patients—supporting use across a broad patient population.
pubmed.ncbi.nlm.nih.gov/41774517/
@oncoalert.bsky.social

Early View | Haematologica

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell #lymphoma: results from EPCORE NHL-2 haematologica.org/article/view... #hvhebron #hemat [Text complet]

NEWS
You Might Have Missed

@lymphomacancerawareness
@rhhs_lls
@non_hodgkins_lymphoma
@lymphomacommunity

#lymphoma #health #wellness #mmj #mmjpatient #mmjcommunity #selfcare #healthcare #patientcare #eduction #care

🎯#CaseReport A 69-year-old male patient with mantle cell #lymphoma accompanied by eosinophilia➡️Following immunochemotherapy, the Pt achieved lymphoma remission, and eosinophil levels returned to normal

journals.sagepub.com/share/UDQ44M...

#CanSky #OncoSky

A close up image of two hands working at a laptop, with overlaid graphics of data charts shown hovering over the keyboard. Below is a blue banner with the wording "New study assesses long-term outcomes for patients given a targeted cancer drug for the treatment of marginal zone lymphoma" and in the top left is the SCTU logo.

A new study will assess long-term outcomes for patients with marginal zone #lymphoma (MZL) who were given a targeted cancer treatment.

The BRAMble study is using real-world data, particularly in high-risk older and more frail patients.

Read more - bit.ly/4swUeXg

Court Approves Notification of Class Action Settlement for Farmers and Landscapers Exposed to Herbicides A recent court decision has paved the way for a class action settlement involving farmers, landscapers, and others exposed to harmful herbicides like Roundup.

Court Approves Notification of Class Action Settlement for Farmers and Landscapers Exposed to Herbicides #USA #Class_Action #St._Louis #Lymphoma #Roundup

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma - PubMed This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using …

Real-world outcomes for CD19‑directed CAR T‑cell therapy (lisocabtagene maraleucel) in patients with relapsed or refractory large B-cell #lymphoma

pubmed.ncbi.nlm.nih.gov/41774517/

On behalf of Course Director Dr. @gillessa.bsky.social, we invite you to join us April 10–11 for the 10th Anniversary MSK Symposium on #Lymphoma, bringing together distinguished experts from @mskcancercenter.bsky.social and leading institutions around the world. Learn more: bit.ly/lymphoma2026

Surviving cancer (twice) stunted Mateo Goldman’s growth. The Duxbury sophomore found a home on the mat. - The Boston Globe Goldman has been cancer-free since beating lymphoma a second time in 2021, and after struggling with football he discovered wrestling and has found success at 113 pounds.

After beating acute lymphoblastic #lymphoma twice, high‑school student Mateo Goldman is now thriving as a varsity wrestler, proving that life after cancer can be powerful, competitive, and full of joy. #TCSC #CancerSurvivor #ChildhoodCancer www.bostonglobe.com/2026/01/31/s...